Compare

Prestige Consumer Healthcare Inc. vs Acadia Pharmaceuticals Inc vs Madrigal Pharmaceuticals, Inc. vs Indivior Pharmaceuticals, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	Prestige Consumer Healthcare Inc. PBH	Acadia Pharmaceuticals Inc ACAD	Madrigal Pharmaceuticals, Inc. MDGL	Indivior Pharmaceuticals, Inc. INDV
Year ended	2026-03-31	2025-12-31	2025-12-31	2025-12-31
Revenue	$1.09B	$1.07B	$958.40M	$1.24B
Revenue growth (YoY)	-4.3%	+11.9%	+432.1%	+4.3%
Gross margin	54.7%	91.7% (computed)	n/a	80.2%
Operating margin	28.4%	9.8%	-31.3%	21.1%
Net margin	17.5%	36.5%	-30.1%	16.9%
Net income	$190.30M	$391.00M	-$288.28M	$210.00M
EPS (Diluted)	$3.91	$2.30	-$12.85	$1.64
Operating cash flow	$257.63M	$109.84M	-$189.55M	-$27.00M
Free cash flow	$246.45M	$105.15M	-$190.02M	-$93.00M
Cash & equivalents	$63.87M	$177.69M	$198.69M	$195.00M
Total assets	$3.49B	$1.56B	$1.26B	$1.20B
Total liabilities	$1.61B	$336.81M	$656.90M	$1.30B
Shareholders' equity	$1.89B	$1.23B	$602.69M	-$98.00M
Return on year-end equity	10.1%	31.9%	-47.8%	n/a
Shares outstanding	n/a	170.31M	22.84M	n/a

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	Prestige Consumer Healthcare Inc.	Acadia Pharmaceuticals Inc	Madrigal Pharmaceuticals, Inc.	Indivior Pharmaceuticals, Inc.
Latest	$1.09B Ended 2026-03-31	$1.07B Ended 2025-12-31	$958.40M Ended 2025-12-31	$1.24B Ended 2025-12-31
1 year earlier	$1.14B Ended 2025-03-31	$957.80M Ended 2024-12-31	$180.13M Ended 2024-12-31	$1.19B Ended 2024-12-31
2 years earlier	$1.13B Ended 2024-03-31	$726.44M Ended 2023-12-31	$0 Ended 2023-12-31	$1.09B Ended 2023-12-31
3 years earlier	$1.13B Ended 2023-03-31	$517.24M Ended 2022-12-31	$0 Ended 2022-12-31	$901.00M Ended 2022-12-31
4 years earlier	$1.09B Ended 2022-03-31	$484.14M Ended 2021-12-31	$0 Ended 2021-12-31	n/a